Rubin Robert T, Rhodes Michael E, Czambel R Kenneth
Center for Neurosciences Research, Drexel University College of Medicine, Allegheny General Hospital, 320 East North Ave., Pittsburgh, PA 15212-4772, USA.
Psychiatry Res. 2002 Dec 30;113(3):255-68. doi: 10.1016/s0165-1781(02)00263-9.
Leptin inhibits appetite by activating several neuroendocrine systems, including the hypothalamo-pituitary-adrenal cortical (HPA) axis. In turn, chronically elevated glucocorticoids increase circulating leptin. HPA axis hyperactivity occurs in 30-50% of patients with major depression, but the few prior reports of leptin measurements in this illness have shown inconsistent results. We, therefore, measured plasma leptin in 12 female and 8 male unipolar major depressives and 12 female and 8 male individually matched normal controls administered low-dose physostigmine (PHYSO) and arginine vasopressin (AVP) to stimulate the HPA axis. The subjects underwent four test sessions 5-7 days apart: PHYSO (8 microg/kg IV); AVP (0-08 U/kg IM); PHYSO+AVP; and saline control. Serial blood samples were taken before and after pharmacologic challenge and analyzed for leptin, ACTH(1-39), cortisol and AVP. Estradiol and testosterone also were measured at each test session. PHYSO and AVP produced no side effects in approximately half the subjects and predominantly mild side effects in the other half, with no significant patient-control differences. Correlations between side effects (absent or present) after PHYSO or AVP and the corresponding leptin responses were non-significant in all groups. Baseline plasma leptin concentrations (mean+/-S.D.) were significantly higher in the female patients compared to the female controls (22.5+/-13.9 ng/ml vs. 12.3+/-9.7 ng/ml), whereas they were similar in the male patients and the male controls (3.9+/-1.4 ng/ml vs. 3.6+/-2.0 ng/ml). Leptin concentrations following PHYSO remained unchanged from baseline, indicating that the short-lived ACTH and cortisol increases produced by PHYSO did not affect leptin secretion. In contrast, AVP administration, while also increasing ACTH and cortisol, significantly suppressed leptin, more so in the women than in the men. Baseline leptin and the leptin decrease after AVP were moderately positively correlated with the Hamilton Depression Scale 'somatization' factor in the female patients (r=0.50) and more strongly correlated with the 'mood-depression' factor in the male patients (r=0.81). These findings indicate a sexual diergism (functional sex difference) in plasma leptin measures between major depressives and matched normal controls.
瘦素通过激活多个神经内分泌系统(包括下丘脑 - 垂体 - 肾上腺皮质(HPA)轴)来抑制食欲。反过来,长期升高的糖皮质激素会增加循环中的瘦素。30%至50%的重度抑郁症患者存在HPA轴功能亢进,但此前关于该疾病中瘦素测量的少数报告结果并不一致。因此,我们测量了12名女性和8名男性单相重度抑郁症患者以及12名女性和8名与之个体匹配的正常对照者的血浆瘦素水平,这些对照者接受低剂量毒扁豆碱(PHYSO)和精氨酸加压素(AVP)以刺激HPA轴。受试者每隔5 - 7天进行四个测试阶段:PHYSO(8微克/千克静脉注射);AVP(0.08单位/千克肌肉注射);PHYSO + AVP;以及生理盐水对照。在药物激发前后采集系列血样,分析瘦素、促肾上腺皮质激素(1 - 39)、皮质醇和AVP。在每个测试阶段还测量了雌二醇和睾酮。大约一半的受试者中,PHYSO和AVP未产生副作用,另一半主要产生轻度副作用,患者与对照之间无显著差异。在所有组中,PHYSO或AVP后副作用(出现或未出现)与相应的瘦素反应之间的相关性均不显著。女性患者的基线血浆瘦素浓度(平均值±标准差)显著高于女性对照(22.5±13.9纳克/毫升对12.3±9.7纳克/毫升),而男性患者和男性对照则相似(3.9±1.4纳克/毫升对3.6±2.0纳克/毫升)。PHYSO后瘦素浓度与基线相比保持不变,表明PHYSO产生的短暂促肾上腺皮质激素和皮质醇增加并未影响瘦素分泌。相比之下,AVP给药虽然也增加促肾上腺皮质激素和皮质醇,但显著抑制了瘦素,女性比男性更明显。女性患者中,基线瘦素和AVP后瘦素降低与汉密尔顿抑郁量表“躯体化”因子呈中度正相关(r = 0.50),男性患者中与“情绪抑郁”因子相关性更强(r = 0.81)。这些发现表明重度抑郁症患者与匹配的正常对照者之间血浆瘦素测量存在性别差异(功能性性别差异)。